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Human herpesvirus-6 (HHV-6), like all the other her-
pes viruses, remains latent in host cells after pri-
mary infection but can be reactivated in immuno-
compromised patients causing fever, skin rash,
bone marrow (BM) suppression, pneumonitis,
sinusitis and meningoencephalitis. We describe the
case of a man with chronic myelogenous leukemia
who developed encephalitis associated with acute
graft-versus-host disease two months after a T-cell-
depleted mismatched peripheral blood stem cell
transplant. Magnetic resonance images of the brain
revealed multiple bilateral foci of signal abnormali-
ty. HHV-6 was the only pathogen detected in cere-
brospinal fluid by PCR. Treatment with both ganci-
clovir and foscarnet was unsuccessful and the
patient gradually deteriorated and died. Other cas-
es of HHV-6 encephalitis after bone marrow trans-
plantation are reviewed.
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In the setting of bone marrow transplantation(BMT), infection by the opportunistic pathogenhuman herpesvirus-6 (HHV-6) is associated with
fever, cutaneous rash, sinusitis, pneumonitis and
delayed engraftment or marrow suppression; it has
also been connected to a single fatal case of menin-
goencephalitis.1-4 However, only a few other cases of
HHV-6 encephalitis after BMT have been report-
ed.5-11 We describe another case of fatal HHV-6
encephalitis following a mismatched stem cell
transplantation. The clinical features of the previ-
ously reported cases are reviewed.
Case report
A 47-year old man with blastic crisis of chronic
myelogenous leukemia received a T-cell-depleted
peripheral blood cell (PBSC) transplant from his
haploidentical 3-loci mismatched daughter, in May
1998. Pre-transplant conditioning included 8 Gy
total body irradiation in a single fraction, fludara-
bine (200 mg/m2 over 5 days), thiotepa (10 mg/kg
on one day) and rabbit antithymocyte globulin (25
mg/kg over 5 days). Granulocyte colony-stimulating
factor (G-CSF) mobilized PBSCs were depleted of T-
and B-cells and enriched for CD34+ cells using the
Isolex 300i device (Baxter, Irvine, CA, USA). The final
inoculum consisted of 11.4106 CD34+ cells/kg and
3.4104 CD3+ cells/kg recipient b.w. No post-trans-
plant immunosuppressive treatment was given. Anti-
cytomegalovirus (CMV) prophylaxis consisted of
ganciclovir (10 mg/kg/day) during the conditioning
followed by foscarnet (90 mg/kg/day). The absolute
neutrophil count reached 0.5109/L on day +11,
platelet count reached 25109/L on day +39. On day
+6, the patient developed signs of hepatic veno-
occlusive disease, which resolved with supportive
therapy. Acute graft-versus-host disease (a GvHD)
was diagnosed on day +35. Initially confined to the
skin it extended to the liver on day +67 and to the gut
on day +71 despite therapy with methotrexate, cyclo-
sporine and prednisone. Pneumonitis developed on
day +62; bronchoalveolar lavage was negative for
common bacterial, fungal and viral pathogens (not
including HHV-6 or respiratory syncytial virus). On
day +67 the patient developed fever, severe mental
confusion, visual and auditory hallucinations and 10-
20 sec seizures characterized by psychomotor agita-
tion and tonic-clonic jerks of the head and arms.
Neurologic examination and CT scan were normal.
Magnetic resonance imaging (MRI) on day +68 was
negative. Analysis of the cerebrospinal fluid (CSF),
obtained via lumbar puncture on day +70, revealed
clear CSF, with normal protein and glucose content,
negative for common bacterial and fungal patho-
gens, CMV and herpes simplex virus (HSV). Empiri-
cal therapy was acyclovir (30 mg/kg, i.v.), from day
+69 to +76. As CMV antigenemia was detected on
day +76 (200 positive cells/slide), acyclovir was
replaced by ganciclovir (10 mg/kg) from day +77 to
+90,  which reduced CMV antigenemia to 6 positive
cell/slide on day +86. The neurologic signs and men-
tal status of the patient remained unchanged. A sec-
ond MRI on day +80 showed bilateral foci of signal
abnormality in the grey matter i.e. in the medial tem-
poral lobes, the uncus and anterior part of the para-
hippocampal gyrus (Figure 1). Contrast scanning
with gadolinium showed neither lesions nor
meningeal enhancement. The patient’s platelet and
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white blood cell counts decreased significantly from
133109/L on day +67 to 5109/L on day +88; and
from 7.33109/L on day +80 to 2109/L on day +90,
respectively. Foscarnet (180 mg/kg/day) was added
to ganciclovir from day +80, but after a transient
improvement in mental status, the patient deterio-
rated with progressive stupor and coma, until death
on day +90.
PCR analysis and hybridization of the amplified
product with an internal oligonucleotide probe was
used as described12 for viral detection in crude
extracts of serum and CSF samples13 collected on
days +67 and +70 respectively. Herpesvirus (HSV-1
and 2, VZV, EBV, HHV-8, CMV, HHV-7), adenovirus,
and polyomaviruses (JC and BK) DNA were not
detected. HHV-6 DNA (ZVH14 region)12 was identi-
fied in both samples providing the only data for diag-
nosis, as the CSF biochemistry was not informative
and a CT scan and MRI were negative in this early
phase of the disease. Cells from the donor were not
available for PCR analysis to determine whether
HHV-6 had been transmitted from the donor.
HHV-6 encephalitis in mismatched BMT
*The authors suggest that an earlier episode of meningoencephalitis, occurring about 15 weeks after transplantation,  was due to an undiagnosed chronic HHV-6
infection of the brain (3). §The diagnosis in this patient was meningoencephalitis. Abbreviations: Hodgkin’s disease (HD); B-cell non-Hodgkin’s lymphoma (B-NHL);
Chronic myelogenous leukemia (CML); Respiratory syncytial virus (RSV).
/ Disease/
transplantation
Onset
(Time after
transplantation)
Neurological
symptoms
CT MRI EEG Liquor Other clinical
symptoms
Outcome Diagnosis of
HHV-6
encephalitis
Ref.
HD/
allo-identical
5 months* Loss of short term
memory
disorientation
somnolence
incontinence
Normal Normal ND WBC 3/mL
Glucose 53 mg/dL
Protein 94 mg/dL
GVHD Fatal
(7 days
after onset
of symptoms)
HHV-6 late
antigen in
autopsy brain
(white-frontal-
matter and grey
matter-
hippocampus)
(3)
CML/
allo-related
24 days Confusion ND Demyelynation/
edema in
hippocampus
ND ND High fever No response
(foscarnet)
HHV-6 DNA
in serum
(5)
B-NHL/
autologous
56 days Muscle tremor
confusion/coma
increased tone
Normal Normal Focal temporal
lobe activity
WBC 5/m3
Glucose 4.68 mmol/L
Protein 0.59 g/L
Pneumonia Recovery
(ganciclovir)
HHV-6 DNA
in CSF
(6)
T-ALL/
allo-identical
15 months Ataxia, lethargia,
seizures
Pansinusitis Normal ND WBC 53/m3
Glucose normal
Protein 101 mg/dL
Fever rash
pneumonia
(RSV)
BM
suppression
Recovery
(foscarnet)
HHV-6 DNA in
CSF
Shell vial
in CSF
(7)
CML/
allo-unrelated
20 days Generalized
seizures,
visual
hallucinations
Normal Foci of signal
cortical
abnormality
(grey matter
-frontal, temporo-
parietal, occipital
lobes)
Periodic sharp
waves with
temporal
predominance
WBC absent
Glucose 63 mg/dL
Protein 0.26 g/L
GVHD skin
and gut
Fatal
(2 weeks
after onset
-ganciclovir
plus
foscarnet-)
HHV-6 DNA
in CSF
(8)
AML/
allo-unrelated
(2nd transplant)
8 months Cerebellar
syndrome,
transient cranial
nerve palsies,
amnesia, frontal
alterations§
Cerebellar
atrophy
Cerebellar atrophy Increased theta
waves in
temporal lobes
WBC 24/m3
Protein 1.5g/L
Fever,
skin rash,
GVHD, BM
suppression,
serous
effusions
Recovery
(foscarnet plus
ganciclovir)
HHV-6 DNA in
CSF/PBMCs
/BM
(9)
CML/
allo-unrelated
26 days Loss of short term
memory,
personality
change, tonic-
clonic seizures,
coma
Normal Edema with
hemorrhage in
temporal lobes
(+32 days after
transplantation)
Burst of sharp
waves
WBC 8/µL
Glucose normal
Protein normal
Fever, GVHD Fatal
(immuno-
globulins)
HHV-6 DNA in
CSF
(10)
?/
allo-identical
22 days Confusion,
excitement,
uncontrollable
muscle
movements
Normal ND Mild diffuse
abnormality
WBC 2/mL GVHD Recovery
(ganciclovir)
Death of
bleeding
HHV-6 DNA in
CSF
(11)
?/
allo-unrelated
10 days Somnolence,
speech
abnormalities,
increased reflexes
Normal Normal Mild diffuse
abnormality
WBC absent
Albumin 538 mg/L
GVHD Improvement
(foscarnet)
Death of organ
failure
HHV-6 DNA in
CSF/PBMCs
(11)
?/
allo-unrelated
18 days Headache,
seizures, coma,
increased reflexes
Subarachnoid
bleeding
Normal Severe diffuse
abnormality
WBC 6/mL
Albumin 12,880 mg/L
GVHD Fatal (7 days
after the onset
–foscarnet)
HHV-6 DNA in
CSF/ autoptic
brain
(11)
?/
allo-unrelated
64 days Confusion speech
abnormalities, loss
of muscle
ccordination
Low attenuated
changes
Old hemorrhage ND WBC 49/mL
Albumin 941 mg/L
Recovery
(foscarnet)
HHV-6 DNA in
CSF/PBMCs
(11)
?/
allo-unrelated
75 days Confusion,
somnolence,
vomiting
Normal ND Pronounced
pathologic
episodes
WBC 4/mL
Albumin 965 mg/L
GVHD Recovery
(foscarnet)
HHV-6 DNA in
CSF/PBMCs
(11)
CML/
allo-
haplo-identical
67 days Confusion, visual
hallucinations,
psicomothor
agitation,
seizures
Normal Normal
(+68 days after
transplantation)
Foci of signal
cortical
abnormality
(grey matter
temporal lobes)
(+80 days after
transplantation)
ND WBC absent
Glucose normal
Protein normal
Fever
GVHD skin
and liver
Pneumonia
Cytopenia
Fatal
(13 days
after the onset
-ganciclovir
plus
foscarnet-)
HHV-6 DNA
in CSF/ serum
This
report
Table 1. Updated review of the reported cases of HHV-6 encephalitis after BMT.
Discussion
Few cases of HHV-6 encephalitis have been report-
ed in bone marrow transplant patients and detailed
cases histories are available for only twelve plus our
present case (Table 1). These data show HHV-6
encephalitis has occurred in autologous and allo-
geneic (related and unrelated) BM and peripheral
blood stem cell transplantation (Table 1). Remark-
ably 4 of the 8 patients for whom a precise diagno-
sis was reported were affected by CML. HHV-6
encephalitis may occur at any time after transplan-
tation. The temporal lobe and hippocampus, as
demonstrated either by MRI findings or by the direct
immunolocalization of the virus in affected tissues
were involved in five cases (4 CML and 1 HD). Of the
other eight cases clinical evidence of encephalitis was
associated in 1 with cerebellar atrophy, in 2 with
hemorrhage and in five with no neuro-radiological
abnormalities. All these latter five patients respond-
ed well to anti-viral therapy. From the clinical point
of view seizures and increased tone are frequently pre-
sent. This observation may be consistent with HHV-
6 localization in the hippocampus. 
In our patient as in 8 others, HHV-6 infection was
associated with GvHD. The link between HHV-6
infection and GvHD is still under debate with three
studies confirming the association1,14,15 and two oth-
ers not.16,17
In vitro studies have clearly demonstrated HHV-6
sensitivity to ganciclovir, and/or foscarnet.4 The
death of 4/11 treated patients despite this anti-viral
therapy suggests that in immunosuppressed patients
HHV-6 may be resistant to all known anti-virals. New
anti-viral agents such as cidofovir may offer hope for
these patients.
In conclusion, after primary infection HHV-6 can
remain latent in host cells and the grey and white mat-
ter of the human brain are common reservoirs.18 In
immunocompromised patients the virus may be reac-
tivated and HHV-6 infection should be carefully con-
sidered in the differential diagnosis of causes of
encephalitis occurring in the setting of BMT. PCR
analysis of CSF for HHV-6 DNA is recommended for
early diagnosis. This test is the only diagnostic tool
available when biochemical analyses of CSF, CT scan
and MRI findings are not informative.
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